Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 28, 2024Future OncologyOpen Access

Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen

View Full Paper
Ask AI
Bookmark
Share

Authors

JAJeremy S. AbramsonUniversity of Southern CaliforniaSSScott R. SolomonNorthside HospitalJAJon ArnasonBeth Israel Deaconess Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Abramson et al. (2024) studied this question.

synapsesocial.com/papers/68e71fd7b6db643587699213https://doi.org/10.2217/fon-2023-0898
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM2025 · 1 citations
  2. 2Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study.2024 · 18 citations
  3. 3A new era for transplant-ineligible R/R LBCL patients: what’s changing?2026
  4. 4Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): First results from CIBMTR.2026
  5. 5Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study2024 · 147 citations